Gilead Sciences Inc. (Nasdaq: GILD) reported disappointing results from a trial of its hepatitis C treatment GS-7977. Shares of the biopharmaceutical plummeted $8.19 to $46.62.
Gilead Reports Disappointing Results
February 17, 2012 at 11:10 AM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.